A cikin kaka na 2007, Kwamitin rigakafi na Quebec (CIQ) ya gabatar da Minista Couillard tare da yanayin aiwatar da shirin. Wannan yana ba da amfani da Gardasil, rigakafin HPV guda ɗaya da Health Canada ta amince da shi a yanzu.

A ranar 11 ga Afrilu, 2008, MSSS ta sanar da sharuɗɗan aikace-aikacen shirin rigakafin HPV. Don haka, daga Satumba 2008, waɗanda za su karɓi rigakafin kyauta sune:

• yan mata 4^e shekara ta makarantar firamare (shekaru 9 da shekaru 10), a matsayin wani ɓangare na shirin rigakafin cutar hanta na B;
• yan mata 3^e sakandare (shekaru 14 da shekaru 15), a matsayin wani ɓangare na allurar rigakafin diphtheria, tetanus da pertussis;
• yan mata 4^e kuma 5^e sakandare;
• 'Yan mata masu shekaru 9 da 10 da suka bar makaranta (ta hanyar cibiyoyin rigakafin da aka keɓe);
• 'Yan mata masu shekaru 11 zuwa 13 ana tsammanin suna cikin haɗari;
• 'yan mata masu shekaru 9 zuwa 18 suna zaune a cikin al'ummomin asali, inda aka fi samun ciwon daji na mahaifa.

Ya kamata a lura cewa 'yan mata masu shekaru 11 zuwa 13 (5^e kuma 6^e shekaru) za a yi alurar riga kafi lokacin da suke cikin 3^e sakandare. Af, 'yan mata matasa daga 4^e kuma 5^e za su je da kansu zuwa sassan da suka dace don karbar allurar kyauta. A ƙarshe, ana iya yiwa mutanen da shirin bai yi niyya ba, akan farashi kusan CA $ 400.

Ɗayan rashin tabbas game da shirin rigakafin HPV ya shafi jadawalin rigakafin.

Tabbas, MSSS tana ba da jadawali wanda ya kai shekaru 5, ga 'yan mata masu shekaru 9 da 10: watanni 6 tsakanin allurai biyu na farko kuma - idan ya cancanta - za a ba da kashi na ƙarshe a cikin 3.^e sakandare, watau shekaru 5 bayan kashi na farko.

Koyaya, jadawalin da masana'anta na Gardasil ya tsara yana ba da watanni 2 tsakanin allurai biyu na farko da watanni 2 tsakanin allurai na biyu da na uku. Don haka bayan watanni 4 an gama allurar.

Shin yana da haɗari a canza jadawalin allurar ta wannan hanyar? A'a, a cewar D^r Marc Steben daga Cibiyar Kiwon Lafiyar Jama'a ta kasa (INSPQ), wanda ya shiga cikin tsara shawarwarin CIQ.

"Kimanin da muka yi ya ba mu damar yin imani cewa 2 allurai, a cikin watanni 6, za su ba da amsawar rigakafi kamar yadda 3 allurai a cikin watanni 6, saboda wannan amsa yana da kyau a cikin ƙarami", in ji shi.

Har ila yau, INSPQ tana bin wani bincike da Jami'ar British Columbia ke gudanarwa a halin yanzu, wanda ke yin nazari kan rigakafin rigakafin da allurai 2 na Gardasil ke bayarwa a cikin 'yan matan da ba su wuce shekaru 12 ba.

Sanarwar shirin rigakafin HPV na duniya ya tayar da muhawara a Quebec, kamar yadda a Kanada a wasu wurare.

Wasu kungiyoyi suna tambayar mahimmancin shirin saboda rashin cikakkun bayanai, misali tsawon lokacin rigakafin rigakafi ko adadin ƙarin allurai waɗanda za a iya buƙata.

Ƙungiyar Ƙungiyoyin Quebec don Shirye-shiryen Iyaye ta Ki amincewa da fifikon da aka ba wa allurar rigakafi da kuma yakin neman ingantacciyar damar yin gwaji.². Don haka ne take neman a dakatar da aiwatar da shirin.

A D^r Luc Bessette ya yarda. "Ta hanyar mayar da hankali kan gwaje-gwaje, za mu iya magance ciwon daji na gaske," in ji shi. Zai ɗauki shekaru 10 ko 20 don sanin tasirin rigakafin. A halin yanzu, ba mu magance matsalar matan da ke fama da cutar sankarar mahaifa ba da ba a yi musu magani ba kuma wadanda za su mutu a wannan shekara, shekara mai zuwa, ko a cikin shekaru 3 ko 4. "

Duk da haka, bai yarda cewa maganin rigakafi na HPV yana haifar da haɗari ga lafiya ba.

Daya daga cikin manyan fa'idodin shirin rigakafin shine "zai karya rashin adalcin barin makaranta," in ji Dokta Marc Steben. Yin watsi da makaranta yana ɗaya daga cikin manyan abubuwan haɗari ga cutar ta HPV da INSPQ ta gano¹.

“Saboda tsarin rigakafin rigakafi ya fi dacewa ga yara mata masu shekaru 9, rigakafin a makarantar firamare ita ce hanya mafi kyau don isa ga yara mata da yawa kafin hadarin barin makaranta. "

A zahiri, sama da kashi 97% na matasa masu shekaru 7 zuwa 14 suna zuwa makaranta a Kanada³.

Anan akwai tebur da ke taƙaita wasu gardama don da kuma adawa da shirin rigakafin HPV. An ɗauko wannan tebur ne daga labarin kimiyya da aka buga a cikin jaridar Turanci The Lancet, a watan Satumbar 2007⁴.